Lamivudine was the first approved inhibitor of hepatitis B virus (HBV) reverse transcriptase (RT). Lamivudine resistance develops in 53% to 76% of patients after 3 years of treatment. We extensively characterized the dynamics of HBV quasispecies variant populations in four HBV-infected patients who developed lamivudine resistance. Virological breakthrough was preceded by 2 to 4 months by the em...

HBV infection is contagious and may be transmitted vertically or horizontally by blood products and body secretions. Over 50% of Iranian carriers have contracted the infection prenatally, making this the most likely route of transmission of HBV in Iran. This study assesses the resistance to Lamivudine in patients with chronic hepatitis B infection using a new ZNA probe Real Time PCR method. To ...

conclusions although the patients carrying m204i mutation were more likely to show lack of responses to lam therapy, lam replacing by other nucleoside/tide analogs plus hbig maybe still effective in decreasing hepatitis b recurrence after liver transplantation. however, it is suggested that drug resistance test should be considered by clinicians during therapeutic management to avoid the follow...

BACKGROUND Lamivudine has been shown to be an efficient drug for chronic hepatitis B (CHB) treatment. AIM To investigate predictive factors of response, using a quantitative method with high sensitivity. METHODS We carried out a prospective trial of lamivudine in 35 patients with CHB and evidence for viral replication, regardless to their HBeAg status. Lamivudine was given for 12 months at ...

Chronic hepatitis B virus (HBV) infection can cause severe liver disease, including cirrhosis and hepatocellular carcinoma. Lamivudine is a relatively recent alternative to alpha interferon for the treatment of HBV infection, but unfortunately, resistance to lamivudine commonly develops during monotherapy. Lamivudine-resistant HBV mutants display specific mutations in the YMDD (tyrosine, methio...

PURPOSE The object of the study was the usefulness of sFas and sFasL concentration in the prognosis of disease development in healthy HBsAg carriers. PATIENTS 34 healthy HBsAg carriers were examined over a three-years period. MATERIAL AND METHODS HBV-DNA was extracted using the Gene Elute Mammalian Genomic DNA Miniprep Kit (Sigma, USA). HBV-DNA concentration and YMDD mutations were measured...